BAX 888

Drug Profile

BAX 888

Alternative Names: FVIII gene therapy

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Baxalta
  • Developer Shire
  • Class Gene therapies
  • Mechanism of Action Blood coagulation factor replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemophilia A

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top